3 news items
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
IVVD
7 May 24
moderate-to-severe immune compromise and for whom alternative COVID-19 treatment options are not clinically appropriate or accessible. Subsequent
Invivyd Announces FDA Authorization For Emergency Use Of PEMGARDA For Pre-Exposure Prophylaxis Of COVID-19
IVVD
22 Mar 24
innovation, Invivyd aims to ensure that vulnerable populations, such as immunocompromised people, have continuous access to innovative antibody
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDAâ„¢ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
IVVD
22 Mar 24
people, have continuous access to innovative antibody therapies. The Company estimates it had approximately $200.6 million of cash and cash
- Prev
- 1
- Next